Organic Active Ingredients TRIZ Cases

Angiotensin II regulates blood pressure via vasoconstriction and sodium reabsorption.

Hydrotropic starch derivatives shield moisture-sensitive prasugrel base particles, preventing solubility loss during storage.

Segmenting the molecular target into specific functional domains allows selective tankyrase inhibition, resolving development complexity while stabilizing Axin.

Maltodextrin powder absorbs cannabis oil to eliminate separation and ensure accurate dosing in hot beverages.

Merging coding and noncoding sequences into one molecule resolves the trade-off between treatment versatility and reliability.

siRNA molecules delivered via AAV vectors silence the SOD1 gene, reducing toxic protein accumulation and slowing amyotrophic lateral sclerosis progression.

Desloratadine overcomes chemotherapy resistance by blocking histamine H1-receptors to boost anti-tumor immunity and improve survival rates.

Cyanomethyl linked benzothiazole compounds inhibit endothelial lipase activity, addressing limited effectiveness of existing treatments for dyslipidemias.

Targeted knockout of inhibitory genes like FAS and PDCD1 overcomes solid tumor barriers, improving T cell persistence and anti-tumor efficacy.

Formula I compounds inhibit ASK1 signaling pathways, reducing apoptosis and inflammatory responses to treat autoimmune disorders and neurodegenerative diseases.

Cyclodextrin inclusion complexes increase meloxicam bioavailability and absorption speed, resolving poor aqueous solubility.

N-substituted imidazole derivatives block indoleamine 2,3-dioxygenase enzymatic activity.

Autoantibodies on nanocarriers bind tumor-released DNA, creating a self-reinforcing delivery loop that sustains drug accumulation over time.

Selective FGFR4 kinase inhibitors reduce off-target effects by targeting specific binding pockets.

CDK8/19 inhibitors reduce neointimal hyperplasia by blocking vascular stem cell differentiation, avoiding statin toxicities.

C4-carboxylic acid-substituted tryptamine derivatives modify molecular structure to enhance receptor binding affinity and reduce off-target side effects.

Combining oncolytic adenovirus with a CDK4/6 inhibitor synchronizes G1 arrest to enhance viral replication in tumor cells.

Azetidine cyclic urea compounds inhibit RIP1 kinase with exceptional metabolic stability, resolving limitations in therapeutic options for necrosis.

Fractionating grape seed extracts using resin chromatography to separate catechin derivatives by molecular weight.

Merging ATR and PARP inhibitors achieves synergistic efficacy in ATM or BRCA2 deficient cancers while reducing toxicity via subtherapeutic dosing.

Combining bitter TAS2R agonists with PDE-5 inhibitors relaxes pulmonary vascular smooth muscle cells.

Purification removes psychoactive impurities like HU-210, eliminating CB1 binding and preventing adverse neurological effects.

Muparfostat inhibits FAK phosphorylation to prevent recurrence in hepatocellular carcinoma patients with microvascular invasion.

SK1-I and ozanimod modulate the sphingosine pathway to induce apoptosis in liver cancer cells while sparing normal hepatocytes.

Specific pharmaceutical compounds inhibit complement C1s to treat disorders mediated by the classical, alternative, and lectin pathways.

One-pot benzaldehyde synthesis eliminates multi-step isolation, reducing impurities and reaction time.

Embedding liposomes in a hydrogel prevents bioactive molecule diffusion, maintaining concentration and stability while enabling targeted cell interaction.

Novel GPR119 agonist compounds activate receptors to stimulate glucose-dependent insulin secretion and GLP-1 release.

Incubating leukocytes with autologous apoptotic cells generates regulatory T cells to suppress immune responses without toxic reagents.

An antagonist targeting the PLA2G2D signaling pathway overcomes immunosuppression to enhance T cell proliferation and treatment efficacy.

Small molecule c-kit inhibitors reduce mature mast cell counts to treat inflammatory conditions like urticaria and mastocytosis.

Selective DNA-PK inhibition sensitizes tumor cells to therapy and shifts repair pathways toward homology-directed editing.

CXCR3 antagonist peptides reduce fibrotic responses while agonist variants enhance viral detection sensitivity.

VPS34 inhibitors block double membrane vesicle formation, reducing viral replication and transmission in coronavirus infections.

Disubstituted pyrazine compounds inhibit tyrosine kinases, resolving the trade-off between efficacy and specificity for JAK family members.

Combining dronedarone with ranolazine achieves synergistic rhythm control without the severe toxicity associated with amiodarone monotherapy.

Dual inhibitor compound overcomes drug resistance by blocking FLT3 and AXL pathways simultaneously.

Phthalazine derivatives cross the blood-brain barrier to treat cognitive diseases while minimizing anxiety-inducing effects.

Androgen receptor ligands stimulate oligodendrocyte proliferation to promote myelin repair.

Isolating the active S-enantiomer reduces required dose amounts while maintaining pharmacokinetic profiles and minimizing adverse events.

Single pyrimidine agents merge microtubule targeting with receptor tyrosine kinase inhibition to overcome pharmacokinetic complexity in cancer therapy.

Administering solriamfetol to lactating mothers and delaying breastfeeding for at least five hours minimizes infant adverse events from drug exposure.

Concentrating fermentation liquid to 40-80% solid content before granulation lowers steam consumption and boosts production efficiency for L-amino acids.

Cold-responsive nanoparticles release chemotherapy and siRNA during cryosurgery to reverse the immunosuppressive tumor microenvironment.

An HDAC inhibitor modulates histone acetylation levels to regulate gene expression and cellular responses in bone tissue.

A CHAPS-based composition enables rapid tissue clearing without denaturation.

Dietary 25-hydroxy vitamin D3 improves boar semen quality and conception rates by counteracting age-related declines in reproductive performance.